

## Review Article

---

# Recent Advances in the Management of Metastatic Breast Cancer

P.P. BAPSY, T.P. SAHOO

---

Management of cancer rests on a multidisciplinary team effort involving basic researchers, radiologists, pathologists, surgeons, radiotherapists, medical oncologists, nurses and psychologists. The above disciplines are currently evolving and contributing to the improved management of breast cancer. Despite advances in the primary and adjuvant systemic therapy in non-metastatic breast cancer, 20-30% of these, present on follow-up with systemic relapse. 1 to 5% of patients are diagnosed to have metastatic disease at presentation<sup>1</sup>, although the incidence is slightly higher in India. Some form of active treatment for advanced breast cancer has been available for more than a century, rendering prospective randomized clinical trial of therapy compared to observation alone unethical<sup>2</sup>. Despite more than three decades of research with the therapeutic modalities, metastatic breast cancer (MBC) remains essentially incurable, with a median survival time of approximate 2 years from the documentation of the metastasis. The median survival is more in patients having bone and soft tissue metastasis compared to those having visceral metastasis. A small percentage of patients even do not relapse for a decade or longer after therapy.

Newly introduced therapies may improve the odds of survival over time for patients with MBC. Several new chemotherapeutic agents have shown response in advanced disease that is resistant to standard medications namely taxanes, capecitabine and vinorelbine. The

introductions of potent and selective aromatase inhibitors (SAI) have resulted in some additional survival<sup>3</sup>. As years of research has failed to cure or show any survival benefit in patients with MBC, the focus is on quality of life (QOL), which is often achieved by the judicious application of both local and systemic therapies.

### PATTERN OF METASTASIS:

Patients with short disease free interval have more of visceral metastasis where as bony metastasis predominates in patients with a longer disease free interval. Invasive lobular cancer is more likely to spread to peritoneum, pleura, adrenal gland, uterus and ovary while those with invasive cancer are more likely to spread to liver, lungs and bone. Patients with ER-positive tumors may have a more indolent clinical course, with slower progression of disease and longer survival. In contrast, patient with ER-negative tumors may have a more aggressive disease, with a shorter disease free interval, more rapid spread and a higher incidence of visceral metastasis with a shorter duration of survival.

### TREATMENT:

**Local:** Metastasis at a single site can be treated with local therapies like surgery or radiation. More extensive tumors are either difficult to resect or to include in one radiation field, thereby rendering them more likely to recur<sup>4</sup>. The efficacy of external RT is well established in dosage ranging from 800-1000cGy (single fraction) to 3000cGy (10 fractions) in the relief of pain due to bony metastasis. Patients with disseminated bony disease can also receive hemibody irradiation. A RTOG trial using 600 cGy for upper hemibody and 800 cGy for the

---

Department of Medical Oncology  
Kidwai Memorial Institute of Oncology  
Dr. M.H. Marigowda Road,  
Bangalore - 560 029  
Correspondence to: P P Bapsy, Email : ppbapsy@yahoo.com

lower half attained a pain relief in 70% of patients<sup>5</sup>. Studies conducted with hemi-body irradiation have also documented a delay in TTP. Radiotherapy has a established role in MBC with metastasis to the brain, spinal cord compression from vertebral body lesions and carcinomatous meningitis. Laminectomy and decompression of a spinal metastasis is indicated in few cases of MBC who have progressive neurological compromise, intractable pain and recurrence of cord compromise following local irradiation. Fracture of long bones can be stabilised with intramedullary nails or prosthesis may be indicated in patients of MBC with massive osteolysis in weight bearing bones. In contrast if there are multiple sites of metastasis, systemic therapy remains the lone option for the patient.

**HORMONAL :**

Though a majority of MBC expresses Estrogen receptor/Progesterone receptor (ER/PR), only 20-40% of patients with hormone responsive breast cancer undergo major tumour regression following endocrine therapy, with an additional 20-30% remaining stable for periods exceeding 6 months<sup>6</sup>. Tamoxifen has been the gold standard of receptor-positive breast cancer for over 2 decades. Over the years, tamoxifen has been compared to ovarian ablation, megestrol acetate, toremefene and Diethyl Stilbesterol among other agents, with none proven superior to tamoxifen.

The development of third generation Aromatase inhibitors has changed the algorithm for the treatment of postmenopausal MBC<sup>7</sup>. In 1990, the SAI's replaced amino-gluthemide and megestrol acetate as the preferred second line hormonal therapy<sup>3,8,9</sup>. Further phase III randomised trials have shown superiority of anastrozole and letrozole over tamoxifen for post -

menopausal hormone sensitive MBC<sup>10-13</sup> leading to its approval as first line therapy in this setting. Pooled results of 2 double-blinded randomized trials have shown anastrozole to prolong time to progression (TTP) in sub group of patients with known positive hormone receptors (HR)<sup>10,12</sup>. In another smaller, double blinded phase II randomised study, confined to women with HR+ve disease, an increased survival for the anastrozole arm was found<sup>13</sup>. Letrozole also showed superiority over tamoxifen with regards to response rate (RR), TTP and survival (upto 2 years) in a single, large, randomised, double blind trial<sup>11</sup>. Letrozole is known to be more potent compared to anastrozole in inhibiting aromatase activity both in vivo and in vitro. A randomised trial comparing the two in advanced breast cancer failing anti-estrogen therapy showed letrozole arm to have a higher RR (19.1% to 12.3%; p<0.013) with statistically insignificant TTP and OS<sup>14</sup>. A comparative phase II study favoring exemestane over tamoxifen has prompted the investigators to extend the study to phase III, the results of which are awaited<sup>15</sup>.

**Table 1: Randomized trials of tamoxifen and aromatase inhibitors as first line therapy for MBC**

Trial/Author (Ref)	Treatments RR (%)	Time to Progression (Months)
TARGET[10]	Tamoxifen 33 Anastrozole 33(p-NS)	8.3m 8.2m (p-NS)
Smith et al[11]	Tamoxifen 21 Letrozole 32 (p<0.0002)	6 m 9.4 m (p<0.0001)
North ] American[12]	Tamoxifen 17 Anastrozole 21 (p-NS)	5.6 m 11.1 m (p<0.005)
Milla-Santos[13]	Tamoxifen 23 Anastrozole 34 (p-not reported)	-5 m -9 m (p<0.05)
EORTC[15]	Tamoxifen 14 Exemestane 44 (p<0.05)	

RR-Response rate, Ref- Reference  
 TARGET-Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study, EORTC-European Organization for Research and Treatment of Cancer, NS-Not Significant

The above studies have made tamoxifen the second line therapy of choice in postmenopausal hormone sensitive MBC. Fulvestrant, a newer anti-estrogen, has been approved in tamoxifen resistant postmenopausal MBC, after phase III studies showed its equivalence to anastrozole; with fulvestrant demonstrating 30% longer mean duration of response. Fulvestrant was well tolerated and the estrogen receptor down regulation with its use did not preclude response to subsequent hormonal therapy<sup>16,17</sup>. Studies are ongoing for biological agents like Iressa, to delay or prevent the onset of hormone resistance<sup>18</sup>.

Hormone sensitive pre-menopausal women with MBC should be treated with tamoxifen with or without ovarian ablation (i.e. oophorectomy or leutinizing hormone receptor (LH-RH)agonists like goserelin). Recent focus has shifted towards treating premenopausal women with the combination of tamoxifen and leutinizing

hormone receptor agonist (LHRH-a). A meta-analysis of 4 trials suggested the combination to be more effective than single agent LHRH-a in terms of RR (39% VS 30%,  $p < 0.03$ ) progression free survival (PFS) (8.7 VS 5.4 months,  $p < 0.003$ ) & overall survival (OS) (2.9 VS 2.5 years,  $p = 0.02$ )<sup>19</sup>. In a small pharmacokinetics study, the SAI vorozole suppressed estrogen levels beyond those achieved by goserelin alone without any significant rise in androgen<sup>20</sup>. Premenopausal patients with MBC, resistant to tamoxifen and LHRH-a should be treated with megestrol acetate. SAI's are not an option as on date for premenopausal women with MBC outside trial setting. Non steroidal benzothioephene selective estrogen receptor modulator, arzoxifene (LY353381) has been tried in a phase II randomized study in two different dosages (20 and 50mg) with response rates varying from 10-25% as per the patient profile<sup>21</sup>.

**Table 2-Randomized phase III trials of taxanes in MBC with minimal or no previous anthracycline exposure**

Study (Ref)	Treatments	RR	(p value)	TTP (p value)	OS (p value)
Single agent					
Chan 1999 [24]	D		47.8%	26 w	15 m
	A		33.3%(0.008)	21 w	14 m
Bishop 1999 [25]	P		29%	5.3 m	17.3 m
	C M F p		35% (0.37)	35% (0.37)	6.4 m (0.25)
	13.9m (0.08)				
Paridaens	P		25%	4.2 m	15.6 m
	A		41%(0.003)	7.5m (<0.001)	18.3m (0.38)
Sledge 2003[27]	P		34%	6.0 m	22.2 m
	A		36%	5.8 m	18.9 m
	A P		47% (,0.0-07)	8.0m (,0.009)	22.0 m
Combination					
Nabholtz 1999[28]	A D		59%	37.3w	3% difference
	A C		47%(0.009)	31.9 w(0.015)	in both arms (NS)
Mackey 2002[29]	D A C		55%	31 w	21 m
	F A C		44% (0.023)	29 w (0.51)	22 m (0.93)

D, docetaxel; P, paclitaxel; A, doxorubicin; C, cyclophosphamide; M, methotrexate; F, 5-fluorouracil;p-prednisone; NA, not available; w, weeks; m, months; RR, response rate; TTP, time to progression; OS, overall survival.

**Chemotherapy (CT):** Doxorubicin is considered the most active cytotoxic agent in the treatment of breast cancer. Its popular use in adjuvant setting has increased the likelihood of anthracycline-resistant MBC. In the above setting taxanes have become the current choice of therapy<sup>22</sup>. Taxanes have been used as a single agent or in combination in MBC. Of the two, docetaxel has proven superior to paclitaxel in a randomised trial<sup>23</sup>. Docetaxel as a single agent has been compared with Doxorubicin alone in 326 anthracycline naïve patients in a phase III randomized trial. Although docetaxel yielded a higher RR the difference in the median TTP, QOL and median OS were not significant<sup>24</sup>. The combination of docetaxel with doxorubicin has been compared with other combination regimen. (**table 2**).

Studies involving paclitaxel monotherapy as first line therapy for MBC have shown conflicting results. A study comparing paclitaxel (175mg/m<sup>2</sup> over 3 hours) with doxorubicin (75mg/m<sup>2</sup>) showed better RR and TTP in favour of

doxorubicin, with no benefit in OS<sup>26</sup>. In contrast, a phase III intergroup trial involving paclitaxel and doxorubicin showed equal OS, although the combination showed better RR & TTP<sup>27</sup>. Another study by Bishop et al comparing paclitaxel to a non-anthracycline combination regimen (CMFp)<sup>25</sup> showed improved OS with no difference in the RR (**table 2**). Paclitaxel in the dosage of 80mg/m<sup>2</sup>/wk was shown to be well tolerated, feasible and effective in a phase II trial for MBC (RR of 40.5%, median TTP of 4.8 months and median OS of 15.8%)<sup>30</sup>. The advantage of the weekly regimen is the low incidence of myelouppression.

In patients previously treated with anthracycline, docetaxel has been compared as a single agent and in combination with capecitabine<sup>31-34</sup>. As a single agent, in 2 of the 3 studies, it showed statistically significant RR, TTP and OS. Docetaxel and capecitabine combination has been shown to be superior to docetaxel alone in terms of RR, TTP and OS with no difference in QOL (**table 3**). There are no available paclitaxel-based phase III trials following anthracycline failure.

**Table3-Randomized phase III Trials of taxanes in MBC after anthracycline failure**

Study	Treatments	RR (p value)	TTP (p value)	OS (p value)
Single-agent				
Nabholtz 1999[31]	D Mito+VBL	30% 11% (,0.0001)	19w 11w (0.001)	11.4 m 8.7m (0.0097)
Sjoström 1999[32]	D M F	42% 21% (<0.001>)	6.3 m 3.0 m (<0.001)	10.4 m 11.1m (0.79)
Bonneterre 2002[33]	D F UN	43% 38.8% (0.69)	6.5m 5.1m	16m 15 m
Combination				
O'Shaugnessy 2002[34]	D+Cape D	41.6% 29.7% (0.006)	6.1 m 4.2 m (0.0001)	14.5 m 11.5m (0.0126)

D, docetaxel; Mito, mitomycin; VBL, vinblastine; M, methotrexate; F, 5-fluorouracil; N, vinorelbine; Cape, capecitabine; NA, not available; w, weeks; m, months; FUN, 5-fluorouracil and vinorelbine.

The impact of CT on survival and QOL in anthracycline-taxane failure is still debated and under evaluation. These regimens either as single agent or in combination have been consistently associated with fewer responses without any effect on median survival. Hence no standard regimen has evolved<sup>35</sup>. Capecitabine, an oral pro-drug of 5-Fluorouracil, in two studies exceeding 130 heavily pretreated patients showed response rates of 18-20% and disease stabilization in 43-48%<sup>36-37</sup>. Capecitabine in the dosage of 2.5gm/m<sup>2</sup>/day has been approved as a third line option for MBC failing anthracycline and taxane. Vinorelbine as a single agent given weekly has shown RR of 20-40%. It has also been tried in combination with 5FU, trastuzumab, anthracycline and cisplatin without any encouraging results in MBC<sup>38-40</sup>. A phase II study of oral vinorelbine at dosage of 60-80mg/m<sup>2</sup>/week showed a RR of 31%. It was found to be an effective, convenient and well tolerated promising alternative to the parenteral therapy<sup>41</sup>. Irinotecan as a single agent has shown some activity in patients previously treated with doxorubicin and taxanes<sup>42</sup>. Liposomal doxorubicin appears to be efficacious and less cardiotoxic than conventional doxorubicin allowing its combination with trastuzumab<sup>43</sup>. The combination has shown little or no activity in patients with anthracycline resistant disease<sup>44</sup>.

Gemcitabine as a monotherapy in MBC has shown responses varying from 37% as a first line therapy to 18% as third line therapy. It has been approved in MBC in combination with paclitaxel as second line therapy. The study comparing gemcitabine alone to its combination with paclitaxel showed RR of 39.3% and 25.6% (p<0.0007) and TTP of 5.4 and 3.5 months (p=0.0013) respectively, the QOL indices favoring the combination<sup>45</sup>. Oxaliplatin combined with 5-FU in a small phase II study showed a RR of 33% with 36% of the patients showing stable disease<sup>46</sup>. A number of newer cytotoxic agents are under evaluation in MBC, such as the multitargeted antifolate Premetrexed (Alimta)<sup>47</sup> and the epothilones, a new promising class of antitubulin agent that seems to lack cross resistance with taxane<sup>48</sup>.

The other areas of debate are regarding the schedule of administration of drugs (as sequential or simultaneous combination therapy) and optimal duration of CT. No conclusion has been reached on these vital issues. The advantages of single agent sequential therapy include administration of each drug at its maximum tolerated dose and avoiding the overlapping toxicity seen with combination regimen. The phase III, 3 arm study comparing sequential scheduling of paclitaxel and doxorubicin, with the combination of both drugs concluded that, although the combination had better RR and median time to treatment failure, it did not improve the survival or the QOL compared to either of the sequential therapy<sup>27</sup>. However simultaneous combination therapy may be appropriate for symptomatic patients with massive tumour burden, in whom better and quick response may be worth the increased toxicity.

CT can be given till best response and then discontinued, to be restarted at the time of progression. It may also be administered on a continual basis till there is progression of the disease or toxicity precludes further therapy. There are advocates of both these approaches. A recent meta-analysis of 4 trials in MBC showed a 23% increase in median OS in women randomised to longer duration of CT<sup>49</sup>. The final

**Table 4- Trastuzumab and CT for HER-2 overexpressing advanced breast cancer**

	CT alone	CT + Trastuzumab	p value
Median survival	20.3months	25.1months	0.046
1 year survival	68%	79%	0.008
TTP	4.6months	7.4months	<0.001
RR %	32	50	<0.001
TTP	Time to Progression		
RR	Response rate		
CT	Chemotherapy		

decision regarding the schedule and duration of therapy should be taken after discussion with the patient. The concept of metronomic CT is to administer the cytotoxic drugs at relatively low doses, which is thought to optimize the

**Table 5 Some of the new biological agents with clinical potential in breast cancer.**

Agent	Class	Target	Current status
ZD1839 (Iressa)	Tyrosine kinase inhibitor	EGFR	Phase II evaluation
Tak 165	Tyrosine kinase inhibitor	Her-2	Phase I evaluation
R-115777 (Zarnestra)	RAS farnesyl transferase inhibitor	RAS and other farnesylated proteins	Activity seen in phase II trials, phase III trials starting
RhuMAB VEGF	Monoclonal	VEGF antibody	Modest activity in Phase II
PS-341	Proteasome inhibitor	Proteasome	Activity in Phase I/II trial as single agent
ZD 6474	Tyrosine kinase inhibitor	VEGFR	Phase I Study
BAY 43-9006	RAF kinase inhibitor	RAF	Phase I study

angiogenic effect of CT. It might be a reasonable option in patients with relatively indolent disease for whom toxicity is the main concern<sup>50</sup>. The role of high dose chemotherapy (HDCT) with autologous stem cell transplantation in the above setting is still a matter of debate. A randomized study comparing HDCT to conventional CT showed no benefit in terms of TTP or OS. The same results were also seen in a French multicentric, randomized study<sup>51</sup>. In contrast, a single center randomized trial has shown survival benefit with HDCT in MBC<sup>52</sup>, but the study is under review as part of a misconduct investigation.

#### **BIOLOGICAL THERAPY:**

Her-2 over expression or amplification occurs in approximately 20-25% of patients with breast cancer. It is associated with aggressive disease and decreased survival<sup>53-54</sup>. Trastuzumab is a humanized mouse monoclonal antibody against the HER-2 protein and is an active and tolerable drug as a first line therapy for MBC<sup>55</sup>. It is given as a weekly schedule (4-mg/kg of loading dose

followed by 2-mg/kg/week). CT when added to trastuzumab has shown increase survival as compared to CT alone in a randomized trial (Table-4)<sup>56</sup>, though no randomized trial is available till date to show superiority of the combination over trastuzumab alone. Pharmacokinetics and safety data suggest less frequent administration of a larger dose of trastuzumab (6mg/kg x q3weekly) might be feasible. A Phase II trial evaluating the safety and pharmacokinetics of trastuzumab and paclitaxel as a 3 weekly schedule have shown a similar plasma drug trough levels and RR with those achieved with the standard weekly regimen<sup>57</sup>.

Number of biological agents targeting a variety of molecular pathways relevant to the biology of breast cancer cell are being tried, the results of which are still awaited (Table-5). Bexarotene, a retinoid X receptor-selective retinoid with preclinical anti-tumour activity in MBC has been tried in a multicenter phase II study as an oral preparation with a RR of approximately 6%<sup>58</sup>.

Bisphosphonates are an integral part in the treatment of women with bone metastases, decreasing the incidence of pathological fractures, pain, and hypercalcemia. Well-conducted, placebo-controlled randomized clinical trials that have demonstrated reduced skeletal morbidity in the bisphosphonate arm. This family continues to grow and the new generation compounds, in view of their increased potency, are expected to be even more efficacious and more convenient to use<sup>59-60</sup>. Zoledronic acid is the most preferred of all bisphosphonates because of its shorter duration of infusion without any compromise on the effect. ASCO 2003 recommends a minimum infusion time of 2 hours for pamidronate and 15 minutes for zoledronic acid with serum creatinine to be monitored before each therapy. Bisphosphonate are not recommended in patients with abnormal bone scan without evidence of bone destruction on imaging. Bisphosphonates given for metastatic pain is recommended along with systemic CT or hormonal therapy<sup>61</sup>.

Patients with widespread bony metastasis can be treated either with Phosphorus 32P which has a expected RR of 80% or Strontium(Sr) 89 which has a RR of 83%. Sr is selectively taken up by tumor involved bone with a ratio of 10:1. 32P and 89Sr are the only agents currently approved for bone metastasis. Newer agents like Samarium 153 and Rhenium 186 are also being studied. Supportive care for MBC as on date also includes chest tube drainage and chemical pleurodesis, pleuroperitoneal shunt, pericardiocentesis and chemical pericardiodesis. Rehabilitation of a case of MBC should be addressed to and taken care as per the patient's personal preferences.

The optimal management of MBC till date remains a therapeutic challenge. The choice of therapy depends upon the hormonal status, prior exposure and toxicity profile. Aromatase inhibitors and tamoxifen are the commonly employed hormonal agents with fulvestrant being approved for tamoxifen resistant cases. The choice and schedule of cytotoxic agent(s) depends upon the patient's disease profile and preference. Biological agents such as trastuzumab and bisphosphonates also play an

important role in the management of MBC. The future lies in the development and use of the newer biological and hormonal agents. As these novel therapies are integrated into daily practice, the main challenge will be to select those patients who are likely to benefit from a specific schedule with minimal toxicity.

#### REFERENCES :

- 1 Ellis M J, Hayes D F, Lippman M E, et al; Treatment of Metastatic Breast Cancer, in 'Disease of the Breast' second edition 2000.
- 2 Beatson G.W. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. *Lancet* 1896; 2:104.
- 3 Buzdar A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. *J Clin Oncol.* 1996;14:2000.
- 4 Harris JR, et al. Time course and prognosis of local recurrence following primary radiation therapy for early breast cancer. *J Clin Oncol.* 1984;2:37.
- 5 Salezar OM, Rubin P, Hendrickson F, et al. Single dose half body irradiation for palliation of multiple bony metastasis from solid tumour. *Cancer* 1986;58:29-36.
- 6 Hotobagyi GN, et al. Endocrine treatment of breast cancer, in Becker KL (ed): Principles and practice of endocrinology and metabolism (ed2). Philadelphia PA, J.B.Lippincott company, 1995:1868-1875
- 7 Mouridsen H, Gershanovich M, et al. The role of aromatase inhibitors in the treatment of MBC. *Semin Oncol* 2003; 30(4 supplement 14): 33-45.
- 8 Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. *J Clin Oncol.* 1998;16:453.
- 9 Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5-mg daily, 0.5-mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. *Letrozole International Trial Group (AR/BC3).* *Ann Oncol.* 1998;9:639.
- 10 Bonnetterre J, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. *Cancer* 2001, 92:2247,
- 11 Mouridsen H, Gershanouich M, Smith R, et al. Phase III study of letrozole versus tamoxifen as first line therapy of advanced breast cancer in post menopausal women : analysis of survival and update of efficacy from the international letrozole breast cancer group. *J Clin Oncol.* 2003, 21 (11):2101-2109.
- 12 Nabholz J.M, Buzdar A, Pollak W, et al. Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in post menopausal women: results of a North American multicentric randomized trial. *J.Clin.Oncol.* 2000;18:3758-3767.

13. Milla - Santos A, Milla L, Rallo L, et al. Anastrozole versus Tamoxifen in hormone dependent advanced breast cancer : a phase II randomized trial. *Am J Clin Oncol.* 2003; 26(3):317-322.
14. Rose C, Vtoraya O, Pluzanska A, et al. An open randomized trial of second line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. *Eur J. Cancer* 2003, 39(16):2318-2327.
15. Paridaens R, Dirix L, Lohrisch C, et al. Promising results with exemestane in the first line treatment of Metastatic Breast Cancer : a randomized phase II EORTC trial with a tamoxifen control. *Ann. Oncol.* 2003 14 (9) :1391-1398.
16. Howell A, Robertson JFR, Quaresma Albano J, et al. Comparison of efficacy and tolerability Faslodex (ICI 182,780) with arimidex (anastrozole) in postmenopausal women with Advanced Breast Cancer - *J.Clin.Onclo.*2002 15:20 (16):3396-3403.
17. Osborne CK, Pippen J, Jones SE, et al. Faslodex (ICI 182,780) shows longer duration of response compared with arimidex (anastrozole) in postmenopausal women with Advanced Breast Cancer - *J. Clin. Oncol.* 2002, 20 (16):3386-3395.
18. Piccart M J, Cardoso F, et al. Progress in systemic therapy for Breast cancer: an overview and perspectives; *Eur J Cancer, supplement Vol.1 No.2* (2003):56-69.
19. Klijn JG, Blamey R W, Boccardo F, et al. Combination LHRH agonist plus tamoxifen treatment is superior to medical castration alone in premenopausal metastatic breast cancer. *J Clin Oncol.* 2001; 19(2):343-353.
20. Dosett M, Coombes RC, et al. Vorozole results in greater estrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced cancer. *Breast Cancer Res Treat* 1999; 56 (1):25-34.
21. Buzdar A, O' shaughnessy, Joyce A, et al. Phase II, randomized, double blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. *J Clin Oncol.* 2003, 21(6):1007-1014.
22. C.Bernard - Marty, Piccart M J, Cardoso F, et al. use and abuse of taxanes in the management of Metastatic Breast Cancer. *Eur J Cancer* (2003 suppl), 39:1978-1989.
23. Ravdin PM, et al. Phase III comparison of docetaxel and paclitaxel in patients with metastatic breast cancer. *Eur J Cancer,* 2003; 1(5):670(a).
24. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. *J Clin Oncol.* 1999, 17:2341-2354.
25. Bishop JF, Dewar J, Toner GC, et al. Initial paclitaxel improves outcome compared with CMFP combination CT as frontline therapy in untreated MBC, *J Clin Oncol.* 1999,17,2355-64.
26. Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicine as first line single agent CT for MBC :a European Organization for Research and Treatment of Cancer randomized study with cross-over. *J Clin Oncol.* 2000,18:724-733.
27. Sledge GW, Neuberg D, Ingle J, et al. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line CT for metastatic breast cancer (MBC): an Intergroup trial (E1193). *J Clin Oncol.* 2003, 21:588-592.
28. Nabholz J, Falkson G, Campos D, et al. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first-line CT for MBC. *Proc Am Soc Clin Oncol.* 1999, 18:127a.
29. Mackey JR, Paterson A, Dirix LY, et al. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line CT (CT) for patients (pts) with metastatic breast cancer (MBC). *Proc Am Soc Clin Oncol.* 2002,21:35a.
30. Sato K, Inoue K, Saito T, et al. Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer : the Saitama Breast cancer Clinical Study Group (SBCCSG - 01). *J Clin Oncol.* 2003; 33 (8):371-6.
31. Nabholz J, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing CT. *J Clin Oncol.* 1999, 17:1413-1424.
32. Sjostrom J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. *Eur J Cancer* 1999, 35:1194-1201.
33. Bonnetterre J, Roche H, Monnier A, et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer anthracycline therapy failure. *Br J Cancer* 2002,87:1210-1215.
34. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. *J Clin Oncol.* 2002, 20:2812-2823.
35. Cardoso F, Di Leo A, Lohrisch C, et al. Second and Subsequent lines of CT for metastatic breast cancer: What did we learn in the last two decades, *Annals of Oncol.ogy* 2001;13:197-207.
36. Blum JL, Jones SE, Buzdar AU, et al. Multicenter Phase II study of capecitabine in paclitaxel refractory metastatic breast cancer; *J Clin Oncol.* 1999;17:485-493.
37. Thuss - Patience PC, Von Minckwitz G, Luck HJ, et al. Capecitabine : a new standard in metastatic breast cancer recurring after anthracycline and taxane containing CT? Results of multicentre phase II trial: *Proc Am Soc Clin Oncol.* 2001;20:66b.



38. Suzuki Y, Saito Y, Tokuda Y, et al. Combination of trastuzumab and vinorelbine in metastatic breast cancer. *Jpn J Clin Oncol.* 2003; 33(10):514-517.
39. Vassilomanolakis M, Koumakis G, Demiri M, et al. Vinorelbine and cisplatin for metastatic breast cancer : a salvage regimen in patients progressing after docetaxel and antracycline treatment. *Cancer Invest.* 2003;21(4):497-504.
40. Lorvidhaya V, Kamnerdsupaphon P, Chitapanarux I, et al. Combination of Vinorelbine and doxorubicin in advanced breast cancer. *Gan To Kagaku Ryoho.* 2003 Aug;30(8):1131-8.
41. Freyer G, Delozier T, Lichinister M, et al. Phase II study of oral vinorelbine in first line advanced breast cancer CT. *J Clin Oncol.* 2003, 21(1):35-40.
42. Perez EZ, Hillman DW, Mailliard JA, et al: Randomized phase II study of 2 schedules of CPT-11 for Patient(s) with refractory MBC an NCCTG Co-Operative group study, *Proc Am Soc Clin Oncol.* 2002;21:52a.
43. Harris L, Batist G, Belt R, et al: Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first line therapy of metastatic breast carcinoma. *Cancer* 2002,94:25-36.
44. Theodoulou M, Campos SM, Batist G, et al. TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis (abstract). *Proc Am Soc Clin Oncol.* 2002,21:55a.
45. O' Shaughnessy J, Nag S, Calderillo-Ruiz, et al. Gemcitabine plus paclitaxel versus paclitaxel as first-line treatment for anthracycline pre-treated metastatic breast cancer: Interim results of a global phase III study. *Proc. Am. Soc. Clin Oncol.* 2003;22:25a.
46. Thuss-patience PC, Von Minckwitz G, Kretzschmar A, et al. Oxaliplatin and 5FU for heavily treated metastatic breast cancer-a preliminary phase II study. *Anticancer drugs* 2003;14:549-553.
47. Miles DW, Smith IE, Coleman RE, et al. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. *Eur J Cancer* 2001,37:1366-1371.
48. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. *Clin Cancer Res* 2001,7:1429-1437.
49. Coates AS, Stockler M, Wilcken N, et al. Controversies in metastatic breast cancer: optimal duration of CT. *American society of clinical oncology educational book* 2003:119-121.
50. Piccart MJ, Bernard-Marty C, Cardoso F, et al. Non-endocrine systemic therapies in advanced breast cancer. *Eur J Cancer (suppl)* 2003:287-298.
51. Stadtmauer EA, O' Neill A, Goldstein LJ, et al. Conventional dose chemotherapy compared with high dose chemotherapy plus autologous haemopoietic stem cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. *N Engl J Med* 2000;342:1069-1076.
52. Bezwoda WR, Seymour L, Dansey RD, et al. High dose chemotherapy with haemopoietic rescue as primary treatment for metastatic breast cancer. *J Clin Oncol* 1995;13:2483-2489.
53. Salmon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science*,1987,235:177-182.
54. Salmon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science* 1989,244:707-712.
55. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first line treatment of HER2-over expressing metastatic breast cancer. *J Clin Oncol.* 2002, 20:719-726.
56. Slamon DJ, Leyland - Jones B, Shak S, et al. Use of CT plus a monoclonal antibody against HER-2 for metastatic breast cancer that over expresses HER-2. *N.Engl. J Med.* 2001;344:783-792.
57. Jones BL, Gelmon K, Ayoub JP, et al. Pharmacokinetics, safety and efficacy of trastuzumab administered every 3 weeks in combination with paclitaxel. *J Clin Oncol.* 2003;21:3965-3971.
58. Esteva FJ, Glaspy J, Baidas S, et al. Multicenter Phase II study of oral Bexarotene for Patients with metastatic breast cancer. *J Clin Oncol.* 2003,Vol.21. No 6: 999-1006.
59. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guidelines on the role of Bisphosphonates in Breast cancer. *J Clin Oncol.* 2000, 18:1378-1391.
60. Tripathy D. et al. Bisphosphonates in oncology: breast cancer and beyond. *Semin Oncol.* 2001,28(4 suppl. 11):86-91.
61. Hilner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of Bisphosphonates and bone health issues in women with Breast cancer. *J Clin Oncol.* 2003; 21, 4042-4057.

